Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma

International Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 761-766

  Prontera, Cesaria ^a,b   Mariani, Barbara ^a   Rossi, Cosmo ^a   Poggi, Andreina ^a   Rotilio, Domenico ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b G Paone Environmental Health Center Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032952694     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990531)81:5<761::AID-IJC16>3.0.CO;2-1     Document Type: Article

References (23)

1. ANDERSON, I.C., SHIPP, M.A., DOCHERTY, A.J.P. and TEICHER, B.A., Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res., 56, 715-718 (1996).
2. BERNHARD, E.J., GRUBER, S.B. and MUSCHEL, R.J., Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. nat. Acad. Sci. (Wash.), 91, 4293-4297 (1994).
3. BIRKEDAL-HANSEN, H., Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol., 7, 728-735 (1995).
4. BROOKS, P.C., STROMBLAD, S., SANDERS, L.C., VON SCHALSCHA, T.L., AIMES, R.T., STETLER-STEVENSON, W.G., QUIGLEY, J.P. and CHERESH, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin ανβ3. Cell, 85, 683-693 (1996).
5. BROWN, P.D. and GIAVAZZI, R., Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol., 6, 967-974 (1995).
6. CHIRIVI, R.G.S., GAROFALO, A., CRIMMIN, M.J., BAWDEN, L.J., STOPPACCIARO, A., BROWN, P.D. and GIAVAZZI, R., Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58, 460-464 (1994).
7. DECLERCK, Y.A., PEREZ, N., SHIMADA, H., BOONE, T.C., LANGLEY, K.E. and TAYLOR, S.M., Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res., 52, 701-708 (1992).
8. DUFFY, M.J., The role of proteolytic enzyme in cancer invasion and metastasis. Clin. exp. Metastasis, 10, 145-155 (1992).
9. FRIDMAN, R., TOTH, M., PENA, D. and MOBASHERY, S., Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res., 55, 2548-2555 (1995).
10. HEPPNER, K.J., MATRISIAN, L.M., JENSEN, R.A. and RODGERS, W.H., Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Amer. J. Pathol., 149, 273-282 (1996).
11. ISIS-4 (FOURTH INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP, ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet, 345, 669-685 (1995).
12. JACKSON, W.E., HOLMES, D.L., GARG, S.K., HARRIS, S. and CHASE, H.P., Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann. Opthalmol., 24, 99-103 (1992).
13. KOHN, E.C. and LIOTTA, L.A., Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res., 55, 1856-1862 (1995).
14. LEVER, A.F., HOLE, D.J., GILLIS, C.R., MCCALLUM, I.R., MCINNES, G.T., MACKINNON, P.L., MEREDITH, P.A., REID, J.L. and ROBERTSON, J.W.K., Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet, 352, 179-184 (1998).
15. LIOTTA, L.A., STEEG, P.S. and STETLER-STEVENSON, W.G., Cancer metastasis and and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
16. NOEL, A., HAJITOU, A., L'HOIR, C., MAQUOI, E., BARAMOVA, E., LEWALLE, J.-M., REMACLE, A., KEBERS, F., BROWN, P., CALDBERG-BACQ, M. and FOIDART, J.-M., Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int. J. Cancer, 76, 267-273 (1998).
17. PRONTERA, C., CRESCENZI, G. and ROTILIO, D., Inhibition by interleukin-4 of stromelysin expression in human skin fibroblasts: role of PKC. Exp. Cell Res., 224, 183-188 (1996).
18. RAY, J.M. and STETLER-STEVENSON, W.G., Gelatinase-A activity directly modulates melanoma cell adhesion and spreading. EMBO J., 14, 908-917 (1995).
19. SLEDGE, G.W., JR., QULALI, M., GOULET, R., BONE, E.A. and FIFE, R., Effect of matrix-metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. nat. Cancer Inst., 87, 1546-1550 (1995).
20. TARABOLETTI, G., GAROFALO, A., BELOTTI, D., DRUDIS, T., BORSOTTI, P., SCANZIANI, E., BROWN, P.D. and GIAVAZZI, R., Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. nat. Cancer Inst., 87, 293-298 (1995).
21. TEICHER, B.A., HOLDEN, S.A., ARA, G., ALVAREZ SOTOMAYOR, E., HUANG, Z.D., CHEN, Y.-N. and BREM, H., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57, 920-925 (1994).
22. VOLPERT, O.V., WARD, W.F., LINGEN, M.W., CHESLER, L., SOLT, D.B., JOHNSON, M.D., MOLTENI, A., POLVERINI, P.J. and BOUCK, N.P., Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. clin. Invest., 98, 671-679 (1996).
23. WATSON, S.A., MORRIS, T.M., ROBINSON, G., CRIMMIN, M.J., BROWN, P.D. and HARDCASTLE, J.D., Inhibition of organ invasion by the matrix-metalloproteinase inhibitor batimastat (BB-94) in two human colon-carcinoma metastasis models. Cancer Res., 55, 3629-3633 (1995).